Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Monique Spillman to Humans

This is a "connection" page, showing publications Monique Spillman has written about Humans.

 
Connection Strength
  
 
 
0.373
  
  1. Shalowitz DI, Lefkowits C, Landrum LM, von Gruenigen VE, Spillman MA. Principles of ethics and critical communication during the COVID-19 pandemic. Gynecol Oncol. 2020 09; 158(3):526-530.
    View in: PubMed
    Score: 0.030
  2. Spillman MA, Sade RM. A Woman in Full. Am J Bioeth. 2018 07; 18(7):32-34.
    View in: PubMed
    Score: 0.026
  3. Guy MS, Qamar L, Behbakht K, Post MD, Sheeder J, Sartorius CA, Spillman MA. Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer. Gynecol Oncol. 2016 Mar; 140(3):518-26.
    View in: PubMed
    Score: 0.022
  4. Spillman MA, Sade RM. I, robotic surgeon. Virtual Mentor. 2014 Oct 01; 16(10):813-7.
    View in: PubMed
    Score: 0.020
  5. Anderson CK, Wallace S, Guiahi M, Sheeder J, Behbakht K, Spillman MA. Risk-reducing salpingectomy as preventative strategy for pelvic serous cancer. Int J Gynecol Cancer. 2013 Mar; 23(3):417-21.
    View in: PubMed
    Score: 0.018
  6. Spillman MA, Sade R. Does fortune foul fidelity? Am J Bioeth. 2011 Sep; 11(9):14-5.
    View in: PubMed
    Score: 0.016
  7. Embry JR, Kelly MG, Post MD, Spillman MA. Large cell neuroendocrine carcinoma of the cervix: prognostic factors and survival advantage with platinum chemotherapy. Gynecol Oncol. 2011 Mar; 120(3):444-8.
    View in: PubMed
    Score: 0.016
  8. Spillman MA, Manning NG, Dye WW, Sartorius CA, Post MD, Harrell JC, Jacobsen BM, Horwitz KB. Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis. Cancer Res. 2010 Nov 01; 70(21):8927-36.
    View in: PubMed
    Score: 0.015
  9. Spillman MA. SGO Washington Update: the price of a profession. Gynecol Oncol. 2010 Oct; 119(1):3-4.
    View in: PubMed
    Score: 0.015
  10. Spillman MA, Lacy J, Murphy SK, Whitaker RS, Grace L, Teaberry V, Marks JR, Berchuck A. Regulation of the metastasis suppressor gene MKK4 in ovarian cancer. Gynecol Oncol. 2007 May; 105(2):312-20.
    View in: PubMed
    Score: 0.012
  11. Spillman MA, Sade RM. Clinical trials of xenotransplantation: waiver of the right to withdraw from a clinical trial should be required. J Law Med Ethics. 2007; 35(2):265-72.
    View in: PubMed
    Score: 0.012
  12. Spillman MA, Schildkraut JM, Halabi S, Moorman P, Calingaert B, Bentley RC, Marks JR, Murphy S, Berchuck A. Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. Gynecol Oncol. 2005 May; 97(2):543-9.
    View in: PubMed
    Score: 0.011
  13. Spillman MA, Berchuck A. Stretching the surface epithelium. J Soc Gynecol Investig. 2004 Dec; 11(8):501-2.
    View in: PubMed
    Score: 0.010
  14. Buckley DN, Lewinger JP, Gooden G, Spillman M, Neuman M, Guo XM, Tew BY, Miller H, Khetan VU, Shulman LP, Roman L, Salhia B. OvaPrint-A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer. Clin Cancer Res. 2023 12 15; 29(24):5196-5206.
    View in: PubMed
    Score: 0.010
  15. Morin K, Rakatansky H, Riddick FA, Morse LJ, O'Bannon JM, Goldrich MS, Ray P, Weiss M, Sade RM, Spillman MA. Managing conflicts of interest in the conduct of clinical trials. JAMA. 2002 Jan 02; 287(1):78-84.
    View in: PubMed
    Score: 0.008
  16. Kandimalla R, Wang W, Yu F, Zhou N, Gao F, Spillman M, Moukova L, Slaby O, Salhia B, Zhou S, Wang X, Goel A. OCaMIR-A Noninvasive, Diagnostic Signature for Early-Stage Ovarian Cancer: A Multi-cohort Retrospective and Prospective Study. Clin Cancer Res. 2021 08 01; 27(15):4277-4286.
    View in: PubMed
    Score: 0.008
  17. Adams CL, Dimitrova I, Post MD, Gibson L, Spillman MA, Behbakht K, Bradford AP. Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma. Exp Mol Pathol. 2019 10; 110:104284.
    View in: PubMed
    Score: 0.007
  18. Richmond AM, Blake EA, Torkko K, Smith EE, Spillman MA, Post MD. Fascin Is Associated With Aggressive Behavior and Poor Outcome in Uterine Carcinosarcoma. Int J Gynecol Cancer. 2017 11; 27(9):1895-1903.
    View in: PubMed
    Score: 0.006
  19. Zhou K, Spillman MA, Behbakht K, Komatsu JM, Abrahante JE, Hicks D, Schotl B, Odean E, Jones KL, Graner MW, Bemis LT. A method for extracting and characterizing RNA from urine: For downstream PCR and RNAseq analysis. Anal Biochem. 2017 11 01; 536:8-15.
    View in: PubMed
    Score: 0.006
  20. Hicks DA, Galimanis CE, Webb PG, Spillman MA, Behbakht K, Neville MC, Baumgartner HK. Claudin-4 activity in ovarian tumor cell apoptosis resistance and migration. BMC Cancer. 2016 10 11; 16(1):788.
    View in: PubMed
    Score: 0.006
  21. Shalowitz DI, Spillman MA, Morgan MA. Interactions with industry under the Sunshine Act: an?example from gynecologic oncology. Am J Obstet Gynecol. 2016 06; 214(6):703-7.
    View in: PubMed
    Score: 0.006
  22. Corr BR, Finlay-Schultz J, Rosen RB, Qamar L, Post MD, Behbakht K, Spillman MA, Sartorius CA. Cytokeratin 5-Positive Cells Represent a Therapy Resistant subpopulation in Epithelial Ovarian Cancer. Int J Gynecol Cancer. 2015 Nov; 25(9):1565-73.
    View in: PubMed
    Score: 0.005
  23. Enriquez VA, Cleys ER, Da Silveira JC, Spillman MA, Winger QA, Bouma GJ. High LIN28A Expressing Ovarian Cancer Cells Secrete Exosomes That Induce Invasion and Migration in HEK293 Cells. Biomed Res Int. 2015; 2015:701390.
    View in: PubMed
    Score: 0.005
  24. Arora KS, Spillman M, Milad M. Bits and pieces: the ethics of uterine morcellation. Obstet Gynecol. 2014 Dec; 124(6):1199-1201.
    View in: PubMed
    Score: 0.005
  25. Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014 Oct; 135(1):38-43.
    View in: PubMed
    Score: 0.005
  26. Hopkins MR, Richmond AM, Cheng G, Davidson S, Spillman MA, Sheeder J, Post MD, Guntupalli SR. Lymphovascular space invasion in robotic surgery for endometrial cancer. JSLS. 2014 Jul-Sep; 18(3).
    View in: PubMed
    Score: 0.005
  27. Guy MS, Cheng G, Post MD, Spillman MA, Behbakht K, Davidson S, Sheeder J, Guntupalli SR. Outcomes of women with atypical glandular cells on preoperative cytology and endometrial cancer. Int J Gynecol Cancer. 2014 Feb; 24(2):266-71.
    View in: PubMed
    Score: 0.005
  28. Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE, Huntsman DG. Type-specific cell line models for type-specific ovarian cancer research. PLoS One. 2013; 8(9):e72162.
    View in: PubMed
    Score: 0.005
  29. Pedersen BS, Konstantinopoulos PA, Spillman MA, De S. Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients. Genes Chromosomes Cancer. 2013 Sep; 52(9):794-801.
    View in: PubMed
    Score: 0.005
  30. Alvarez RD, Gray HJ, Timmins PF, Gibb RK, Edelson M, Fowler JM, Havrilesky LJ, McCauley DL, Nash JD, Rahaman J, Rash JK, Rodabaugh KJ, Powell MA, Bristow RE, Brown JV, Tewari D, Cliby WA, Anastasia P, Robinson WR, Shahin MS, Cantrell LA, Cloven NG, Gold MA, Hope JM, Muntz HG, Sorosky JI, Elkas JC, Frumovitz MM, Jewell E, Spillman MA, Naumann RW. We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies. Gynecol Oncol. 2013 Apr; 129(1):3-4.
    View in: PubMed
    Score: 0.005
  31. Webb PG, Spillman MA, Baumgartner HK. Claudins play a role in normal and tumor cell motility. BMC Cell Biol. 2013 Mar 23; 14:19.
    View in: PubMed
    Score: 0.005
  32. Jambal P, Badtke MM, Harrell JC, Borges VF, Post MD, Sollender GE, Spillman MA, Horwitz KB, Jacobsen BM. Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features. Breast Cancer Res Treat. 2013 Jan; 137(2):431-48.
    View in: PubMed
    Score: 0.005
  33. Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR, Spillman MA, Richer JK. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther. 2012 Dec; 11(12):2556-65.
    View in: PubMed
    Score: 0.004
  34. Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, Lessey BA, Jordan VC, Bradford AP. DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol. 2012 Oct; 127(1):241-8.
    View in: PubMed
    Score: 0.004
  35. Qamar L, Deitsch E, Patrick AN, Post MD, Spillman MA, Iwanaga R, Thorburn A, Ford HL, Behbakht K. Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer. Gynecol Oncol. 2012 May; 125(2):451-7.
    View in: PubMed
    Score: 0.004
  36. Ralston SJ, Spillman MA, Mitchell MF, Mahoney J, Joseph GF. Obstetricians: women's advocates, not adversaries. Am J Bioeth. 2011 Dec; 11(12):57-9.
    View in: PubMed
    Score: 0.004
  37. Stashwick C, Post MD, Arruda JS, Spillman MA, Behbakht K, Davidson SA, Kelly MG. Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Int J Gynecol Cancer. 2011 Nov; 21(8):1422-7.
    View in: PubMed
    Score: 0.004
  38. Badtke MM, Jambal P, Dye WW, Spillman MA, Post MD, Horwitz KB, Jacobsen BM. Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpoint. Breast Cancer Res Treat. 2012 Jan; 131(1):75-87.
    View in: PubMed
    Score: 0.004
  39. Lange CA, Sartorius CA, Abdel-Hafiz H, Spillman MA, Horwitz KB, Jacobsen BM. Progesterone receptor action: translating studies in breast cancer models to clinical insights. Adv Exp Med Biol. 2008; 630:94-111.
    View in: PubMed
    Score: 0.003
  40. Murphy SK, Huang Z, Wen Y, Spillman MA, Whitaker RS, Simel LR, Nichols TD, Marks JR, Berchuck A. Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol Cancer Res. 2006 Apr; 4(4):283-92.
    View in: PubMed
    Score: 0.003
  41. Taub S, Morin K, Sade RM, Spillman MA. Safeguards in the use of DNA databanks in genomic research. Genet Med. 2004 Nov-Dec; 6(6):526-9.
    View in: PubMed
    Score: 0.003
  42. Taub S, Morin K, Spillman MA, Sade RM, Riddick FA. Managing familial risk in genetic testing. Genet Test. 2004; 8(3):356-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.